Validation Data Gallery
Tested Applications
| Positive WB detected in | HepG2 cells |
| Positive IP detected in | HepG2 cells |
| Positive IHC detected in | mouse testis tissue, human ovary tumor tissue, human testis tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
| Positive IF/ICC detected in | Caco-2 cells |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:500-1:2000 |
| Immunoprecipitation (IP) | IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate |
| Immunohistochemistry (IHC) | IHC : 1:250-1:1000 |
| Immunofluorescence (IF)/ICC | IF/ICC : 1:50-1:500 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Published Applications
| KD/KO | See 1 publications below |
| WB | See 11 publications below |
| IHC | See 2 publications below |
| IF | See 3 publications below |
| CoIP | See 1 publications below |
Product Information
24500-1-AP targets SALL4 in WB, IHC, IF/ICC, IP, CoIP, ELISA applications and shows reactivity with human, mouse, rat samples.
| Tested Reactivity | human, mouse, rat |
| Cited Reactivity | human, mouse |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen |
CatNo: Ag17480 Product name: Recombinant human SALL4 protein Source: e coli.-derived, PET28a Tag: 6*His Domain: 1-350 aa of BC111714 Sequence: MSRRKQAKPQHINSEEDQGEQQPQQQTPEFADAAPAAPAAGELGAPVNHPGNDEVASEDEATVKRLRREETHVCEKCCAEFFSISEFLEHKKNCTKNPPVLIMNDSEGPVPSEDFSGAVLSHQPTSPGSKDCHRENGGSSEDMKEKPDAESVVYLKTETALPPTPQDISYLAKGKVANTNVTLQALRGTKVAVNQRSADALPAPVPGANSIPWVLEQILCLQQQQLQQIQLTEQIRIQVNMWASHALHSSGAGADTLKTLGSHMSQQVSAAVALLSQKAGSQGLSLDALKQAKLPHANIPSATSSLSPGLAPFTLKPDGTRVLPNVMSRLPSALLPQAPGSVLFQSPFST 相同性解析による交差性が予測される生物種 |
| Full Name | sal-like 4 (Drosophila) |
| Calculated molecular weight | 1053 aa, 112 kDa |
| Observed molecular weight | 66-75 kDa |
| GenBank accession number | BC111714 |
| Gene Symbol | SALL4 |
| Gene ID (NCBI) | 57167 |
| RRID | AB_2879576 |
| Conjugate | Unconjugated |
| Form | |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | Q9UJQ4 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol{{ptg:BufferTemp}}7.3 |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
Background Information
Sal-like protein 4 (SALL4), also named Zinc finger protein 797, contains 7 C2H2-type zinc fingers and belongs to the sal C2H2-type zinc-finger protein family. SALL4 is a transcription factor that exists in two splice isoforms and regulates transcription in embryonic stem cells, hematopoiesis, and acute myeloid leukemia. SALL4 is activated in fetal liver tissue, silenced in adult liver tissue, and reexpressed as an oncofetal protein in hepatocellular carcinoma (PMID: 26892498, 23758232). SALL4 has two isoforms with predicted molecular weights of 112 kDa (SALL4A) and 66 kDa (unmodified SALL4B), and SALL4B was found to be the dominant endogenous isoform in HCC cell lines. Ectopically expressed SALL4B migrated at 95 kDa modified by ubiquitination, 130 kDa modified by sumoylation (PMID: 23012367).
Protocols
| Product Specific Protocols | |
|---|---|
| IF protocol for SALL4 antibody 24500-1-AP | Download protocol |
| IHC protocol for SALL4 antibody 24500-1-AP | Download protocol |
| IP protocol for SALL4 antibody 24500-1-AP | Download protocol |
| WB protocol for SALL4 antibody 24500-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
| Species | Application | Title |
|---|---|---|
J Exp Clin Cancer Res Pharmacological targeting PTK6 inhibits the JAK2/STAT3 sustained stemness and reverses chemoresistance of colorectal cancer. | ||
Cell Death Dis SALL4 promotes cancer stem-like cell phenotype and radioresistance in oral squamous cell carcinomas via methyltransferase-like 3-mediated m6A modification | ||
Int J Mol Med Integrative transcriptomic analysis unveils FXR as a key regulator of intestinal stemness and inflammation in ulcerative colitis. | ||
J Med Chem Discovery of Highly Potent and Selective IKZF2 Degraders for Cancer Immunotherapy. | ||
J Med Chem Discovery of Novel Potent Triple IKZF1/2/3 Degraders for the Treatment of Hematological Cancers | ||
J Med Chem Discovery of a Series of Orally Bioavailable Androgen Receptor Degraders for the Treatment of Prostate Cancer |